Advances in the management of coronary chronic total occlusions

Emmanouil S. Brilakis; Dimitri Karmpaliotis; Minh N. Vo; Santiago Garcia; Lampros Michalis; Khaldoon Alaswad; Parag Doshi; William L. Lombardi; Subhash Banerjee

doi:10.1007/s12265-014-9556-6

Advances in the management of coronary chronic total occlusions

Emmanouil S. Brilakis, Dimitri Karmpaliotis, Minh N. Vo, Santiago Garcia, Lampros Michalis, Khaldoon Alaswad, Parag Doshi, William L. Lombardi, Subhash Banerjee

Medicine - Veteran's Administration Medical Center

Research output: Contribution to journal › Article › peer-review

26 Scopus citations

Abstract

Chronic total occlusions (CTOs) have been called "the last frontier" of percutaneous coronary intervention (PCI) due to traditionally low success rates and high risk for restenosis and re-occlusion. Recent advances in equipment and crossing techniques have significantly increased CTO PCI success rates while maintaining low risk of complications. Specifically, the retrograde approach and controlled antegrade dissection and re-entry in conjunction with advanced guidewires and microcatheters have significantly improved procedural success rates. Moreover, the introduction of the "hybrid" approach has created a unified framework for operators to approach CTOs in a systematic and efficient fashion. Finally, drug-eluting stents, especially second generation, have improved long-term patency after CTO PCI.

Original language	English (US)
Pages (from-to)	426-436
Number of pages	11
Journal	Journal of cardiovascular translational research
Volume	7
Issue number	4
DOIs	https://doi.org/10.1007/s12265-014-9556-6
State	Published - Jun 2014

Bibliographical note

Funding Information:
Conflict of Interest Dr. Brilakis is a consulting/speaker honoraria from St. Jude Medical, Terumo, Janssen, Sanofi, Asahi, Abbott Vascular, and Boston Scientific and received research support from Guerbet. His spouse is an employee of Medtronic. Dr. Karmpaliotis was supported by speaker bureau, Abbott Vascular, Medtronic, and Boston Scientific. Dr. Vo is a consultant from Boston Scientific. Dr. Garcia received consulting fees from Medtronic; he is a recipient of a career development award from the VA Office of Research and Development. Dr. Michalis has no conflict of interest. Dr. Alaswad received consulting fees from Terumo and Boston Scientific; he is a consultant, with no financial fees, of Abbott Laboratories. Dr. Doshi received consulting fees from Boston Scientific. Dr. Lombardi is a consultant for Abbott Vascular, Bridgepoint Medical, and Medtronic; speaker honoraria from Abbott Vascular, Medtronic, and Terumo; and equity from Bridgepoint Medical. Dr. Banerjee received research grants from Gilead and the Medicines Company, consultant/ speaker honoraria from Covidien and Medtronic, ownership in MDCARE Global (spouse), and intellectual property in HygeiaTel.

Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.

Keywords

Chronic total occlusion
Coronary revascularization
Percutaneous coronary intervention

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1007/s12265-014-9556-6

OpenUrl availability

Full text

Cite this

@article{06c1f884f78b43929d39b83da2a00990,

title = "Advances in the management of coronary chronic total occlusions",

abstract = "Chronic total occlusions (CTOs) have been called {"}the last frontier{"} of percutaneous coronary intervention (PCI) due to traditionally low success rates and high risk for restenosis and re-occlusion. Recent advances in equipment and crossing techniques have significantly increased CTO PCI success rates while maintaining low risk of complications. Specifically, the retrograde approach and controlled antegrade dissection and re-entry in conjunction with advanced guidewires and microcatheters have significantly improved procedural success rates. Moreover, the introduction of the {"}hybrid{"} approach has created a unified framework for operators to approach CTOs in a systematic and efficient fashion. Finally, drug-eluting stents, especially second generation, have improved long-term patency after CTO PCI.",

keywords = "Chronic total occlusion, Coronary revascularization, Percutaneous coronary intervention",

author = "Brilakis, {Emmanouil S.} and Dimitri Karmpaliotis and Vo, {Minh N.} and Santiago Garcia and Lampros Michalis and Khaldoon Alaswad and Parag Doshi and Lombardi, {William L.} and Subhash Banerjee",

note = "Funding Information: Conflict of Interest Dr. Brilakis is a consulting/speaker honoraria from St. Jude Medical, Terumo, Janssen, Sanofi, Asahi, Abbott Vascular, and Boston Scientific and received research support from Guerbet. His spouse is an employee of Medtronic. Dr. Karmpaliotis was supported by speaker bureau, Abbott Vascular, Medtronic, and Boston Scientific. Dr. Vo is a consultant from Boston Scientific. Dr. Garcia received consulting fees from Medtronic; he is a recipient of a career development award from the VA Office of Research and Development. Dr. Michalis has no conflict of interest. Dr. Alaswad received consulting fees from Terumo and Boston Scientific; he is a consultant, with no financial fees, of Abbott Laboratories. Dr. Doshi received consulting fees from Boston Scientific. Dr. Lombardi is a consultant for Abbott Vascular, Bridgepoint Medical, and Medtronic; speaker honoraria from Abbott Vascular, Medtronic, and Terumo; and equity from Bridgepoint Medical. Dr. Banerjee received research grants from Gilead and the Medicines Company, consultant/ speaker honoraria from Covidien and Medtronic, ownership in MDCARE Global (spouse), and intellectual property in HygeiaTel. Copyright: Copyright 2014 Elsevier B.V., All rights reserved.",

year = "2014",

month = jun,

doi = "10.1007/s12265-014-9556-6",

language = "English (US)",

volume = "7",

pages = "426--436",

journal = "Journal of cardiovascular translational research",

issn = "1937-5387",

publisher = "Springer New York",

number = "4",

}

TY - JOUR

T1 - Advances in the management of coronary chronic total occlusions

AU - Brilakis, Emmanouil S.

AU - Karmpaliotis, Dimitri

AU - Vo, Minh N.

AU - Garcia, Santiago

AU - Michalis, Lampros

AU - Alaswad, Khaldoon

AU - Doshi, Parag

AU - Lombardi, William L.

AU - Banerjee, Subhash

N1 - Funding Information: Conflict of Interest Dr. Brilakis is a consulting/speaker honoraria from St. Jude Medical, Terumo, Janssen, Sanofi, Asahi, Abbott Vascular, and Boston Scientific and received research support from Guerbet. His spouse is an employee of Medtronic. Dr. Karmpaliotis was supported by speaker bureau, Abbott Vascular, Medtronic, and Boston Scientific. Dr. Vo is a consultant from Boston Scientific. Dr. Garcia received consulting fees from Medtronic; he is a recipient of a career development award from the VA Office of Research and Development. Dr. Michalis has no conflict of interest. Dr. Alaswad received consulting fees from Terumo and Boston Scientific; he is a consultant, with no financial fees, of Abbott Laboratories. Dr. Doshi received consulting fees from Boston Scientific. Dr. Lombardi is a consultant for Abbott Vascular, Bridgepoint Medical, and Medtronic; speaker honoraria from Abbott Vascular, Medtronic, and Terumo; and equity from Bridgepoint Medical. Dr. Banerjee received research grants from Gilead and the Medicines Company, consultant/ speaker honoraria from Covidien and Medtronic, ownership in MDCARE Global (spouse), and intellectual property in HygeiaTel. Copyright: Copyright 2014 Elsevier B.V., All rights reserved.

PY - 2014/6

Y1 - 2014/6

N2 - Chronic total occlusions (CTOs) have been called "the last frontier" of percutaneous coronary intervention (PCI) due to traditionally low success rates and high risk for restenosis and re-occlusion. Recent advances in equipment and crossing techniques have significantly increased CTO PCI success rates while maintaining low risk of complications. Specifically, the retrograde approach and controlled antegrade dissection and re-entry in conjunction with advanced guidewires and microcatheters have significantly improved procedural success rates. Moreover, the introduction of the "hybrid" approach has created a unified framework for operators to approach CTOs in a systematic and efficient fashion. Finally, drug-eluting stents, especially second generation, have improved long-term patency after CTO PCI.

AB - Chronic total occlusions (CTOs) have been called "the last frontier" of percutaneous coronary intervention (PCI) due to traditionally low success rates and high risk for restenosis and re-occlusion. Recent advances in equipment and crossing techniques have significantly increased CTO PCI success rates while maintaining low risk of complications. Specifically, the retrograde approach and controlled antegrade dissection and re-entry in conjunction with advanced guidewires and microcatheters have significantly improved procedural success rates. Moreover, the introduction of the "hybrid" approach has created a unified framework for operators to approach CTOs in a systematic and efficient fashion. Finally, drug-eluting stents, especially second generation, have improved long-term patency after CTO PCI.

KW - Chronic total occlusion

KW - Coronary revascularization

KW - Percutaneous coronary intervention

UR - http://www.scopus.com/inward/record.url?scp=84903694957&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903694957&partnerID=8YFLogxK

U2 - 10.1007/s12265-014-9556-6

DO - 10.1007/s12265-014-9556-6

M3 - Article

C2 - 24634196

AN - SCOPUS:84903694957

SN - 1937-5387

VL - 7

SP - 426

EP - 436

JO - Journal of cardiovascular translational research

JF - Journal of cardiovascular translational research

IS - 4

ER -

Advances in the management of coronary chronic total occlusions

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this